An investigation of the predictability of carboplatin plasma concentrations in children following dosing on the basis of surface area of renal function

ISRCTN ISRCTN79815499
DOI https://doi.org/10.1186/ISRCTN79815499
Secondary identifying numbers NAG9402
Submission date
01/07/2001
Registration date
01/07/2001
Last edited
01/02/2012
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific title
Study objectivesNot provided at time of registration
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedCancer of brain and nervous system
InterventionPatients receiving two courses of carboplatin are randomised to one of two groups:

1. Group A: Surface area based (course I) followed by renal function based (course II) measurement.
2. Group B: Renal function based (course I) followed by surface area based (course II) measurement.
Intervention typeOther
Primary outcome measureNot provided at time of registration
Secondary outcome measuresNot provided at time of registration
Overall study start date01/01/1993
Completion date28/02/1997

Eligibility

Participant type(s)Patient
Age groupChild
Upper age limit18 Years
SexNot Specified
Target number of participantsNot provided at time of registration
Key inclusion criteria1. Aged under 18 years
2. Receiving carboplatin on at least two occasions
3. Being treated according to listed UKCCSG protocols (NB9001, NB9301, NB8702, GC8901, CNS9204, CNS9102, WAG8702)
4. Tumour site: Neuroblastoma; Extra-cranial germ cell; Brain
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/01/1993
Date of final enrolment28/02/1997

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Sponsor information

Cancer Research UK (CRUK) (UK)
Charity

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom

Phone +44 (0)207 317 5186
Email kate.law@cancer.org.uk
Website http://www.cancer.org.uk
ROR logo "ROR" https://ror.org/054225q67

Funders

Funder type

Charity

Cancer Research UK
Private sector organisation / Other non-profit organizations
Alternative name(s)
CR_UK, Cancer Research UK - London, CRUK
Location
United Kingdom
United Kingdom Children's Cancer Study Group (UKCCSG)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/11/2000 Yes No